This is a StreetInsider.com Premium Only Page

Atossa Therapeutics (ATOS) –

Apr 15, 2024 08:32 AM Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Announce I-SPY 2 Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib

Apr 15, 2024 08:30 AM Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Apr 11, 2024 04:05 PM Form 4 ATOSSA THERAPEUTICS, For: Apr 10 Filed by: Finn Jonathan

Apr 11, 2024 08:30 AM Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Apr 9, 2024 12:00 PM Atossa Therapeutics (ATOS) Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Apr 9, 2024 11:59 AM Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Apr 2, 2024 06:03 AM Form 8-K/A ATOSSA THERAPEUTICS, For: Apr 01

Apr 1, 2024 04:06 PM Form 10-K ATOSSA THERAPEUTICS, For: Dec 31

Apr 1, 2024 04:00 PM Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Apr 1, 2024 04:00 PM Form 8-K ATOSSA THERAPEUTICS, For: Apr 01

Mar 19, 2024 08:31 AM Atossa Therapeutics (ATOS) Provides Five-Year (Z)-Endoxifen Treatment Update

Mar 19, 2024 08:30 AM Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Mar 18, 2024 08:35 AM Form 8-K ATOSSA THERAPEUTICS, For: Mar 15

Mar 18, 2024 08:33 AM Atossa Therapeutics (ATOS) Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Mar 18, 2024 08:30 AM Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Mar 14, 2024 08:35 PM Form 4 ATOSSA THERAPEUTICS, For: Mar 09 Filed by: Cigler Tessa

Mar 14, 2024 08:30 PM Form 3 ATOSSA THERAPEUTICS, For: Mar 09 Filed by: Cigler Tessa

Mar 12, 2024 08:32 AM Atossa Therapeutics (ATOS) Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Mar 12, 2024 08:30 AM Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Mar 12, 2024 08:30 AM Form 8-K ATOSSA THERAPEUTICS, For: Mar 09

Mar 6, 2024 08:30 AM Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Feb 22, 2024 08:30 AM Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Feb 12, 2024 06:06 AM H.C. Wainwright Starts Atossa Genetics (ATOS) at Buy

Feb 7, 2024 08:30 AM Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

Jan 9, 2024 08:31 AM Atossa Therapeutics (ATOS) Issues Letter to Shareholders

Jan 9, 2024 08:30 AM Atossa Therapeutics Issues Letter to Shareholders

Dec 18, 2023 09:00 AM Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus

Dec 4, 2023 08:30 AM Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Nov 20, 2023 08:30 AM Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Nov 17, 2023 04:02 PM Form 4 ATOSSA THERAPEUTICS, For: Nov 15 Filed by: WEAVER GREGORY L

Nov 15, 2023 05:04 PM Form 4/A ATOSSA THERAPEUTICS, For: Nov 15 Filed by: Finn Jonathan

Nov 15, 2023 04:15 PM Form 3 ATOSSA THERAPEUTICS, For: Nov 08 Filed by: Finn Jonathan

Nov 15, 2023 04:06 PM Form 4 ATOSSA THERAPEUTICS, For: Nov 15 Filed by: Finn Jonathan

Nov 13, 2023 09:13 AM Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30

Nov 13, 2023 09:02 AM Form 8-K ATOSSA THERAPEUTICS, For: Nov 13

Nov 13, 2023 09:00 AM Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023 09:01 AM Atossa Therapeutics (ATOS) Appoints Jonathan Finn to its Board

Nov 9, 2023 09:01 AM Form 8-K ATOSSA THERAPEUTICS, For: Nov 09

Nov 9, 2023 09:00 AM Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Oct 30, 2023 01:00 PM Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Oct 17, 2023 08:00 AM Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

Oct 16, 2023 04:01 PM Form 3 ATOSSA THERAPEUTICS, For: Oct 06 Filed by: Rees Heather

Oct 11, 2023 08:30 AM Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

Oct 6, 2023 04:06 PM Atossa Therapeutics (ATOS) Announces CFO Resignation

Oct 6, 2023 04:01 PM Form 8-K ATOSSA THERAPEUTICS, For: Oct 02

Sep 28, 2023 04:29 PM Form 8-K ATOSSA THERAPEUTICS, For: Sep 26

Sep 18, 2023 09:25 AM Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

Sep 18, 2023 08:30 AM Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Sep 8, 2023 06:07 AM Cantor Fitzgerald Starts Atossa Genetics (ATOS) at Overweight, 'Changing the Treatment Paradigm in Breast Cancer'

Aug 31, 2023 06:13 AM Atossa Therapeutics (ATOS) Announces Intas Pharmaceuticals Filed PRG Petition Against one of Patents